Your browser doesn't support javascript.
loading
A retrospective analysis of the frequency of heparin-induced thrombocytopenia in the intensive care unit at a tertiary care center in Riyadh, Saudi Arabia.
Mushtaq, Ali H; Rasheed, Abdulrahman W; Jamil, Mouhamad G; Maghrabi, Khalid; Khoja, Osama; Sajid, Muhammad R; Tamim, Hani; Hijazi, Mohammad; Owaidah, Tarek.
Afiliação
  • Mushtaq AH; Al Faisal University Riyadh, Saudi Arabia.
  • Rasheed AW; Department of Internal Medicine, Cleveland Clinic Foundation Cleveland, Ohio, The United States of America.
  • Jamil MG; Department of Internal Medicine, Cleveland Clinic Foundation Cleveland, Ohio, The United States of America.
  • Maghrabi K; Department of Hematology, King Faisal Specialist Hospital and Research Center Riyadh, Saudi Arabia.
  • Khoja O; Department of Hematology, King Faisal Specialist Hospital and Research Center Riyadh, Saudi Arabia.
  • Sajid MR; Department of Hematology, King Faisal Specialist Hospital and Research Center Riyadh, Saudi Arabia.
  • Tamim H; Al Faisal University Riyadh, Saudi Arabia.
  • Hijazi M; Al Faisal University Riyadh, Saudi Arabia.
  • Owaidah T; Department of Hematology, King Faisal Specialist Hospital and Research Center Riyadh, Saudi Arabia.
Am J Blood Res ; 13(6): 198-206, 2023.
Article em En | MEDLINE | ID: mdl-38223315
ABSTRACT

BACKGROUND:

Heparin-induced thrombocytopenia (HIT) is an extremely serious and potentially fatal condition that can develop in patients taking heparin-based medications, such as unfractionated heparin (UFH) or low-molecular-weight heparin (LMWH). The incidence and risk factors for HIT in critically ill patients, however, are not well defined.

METHODS:

We retrospectively collected data on HIT test results, route of heparin administration, age, sex, heparin type (UFH or LMWH), and date of illness from patients admitted to the intensive care unit (ICU) and regular nursing floor (non-ICU) at our hospital between January 2011 and December 2014. We screened patients for HIT using the 4T score and confirmed the diagnosis through laboratory testing (direct enzyme immunoassay immunoglobulin G [IgG] or a platelet-activating antibody).

RESULTS:

We screened a total of 946 patients, 56 (5.9%) of whom were positive for HIT. Among 776 patients receiving UFH and 180 receiving LMWH, 2.8 and 6.6% developed HIT, respectively (P = 0.051). We then classified our patients into two groups ICU, and non-ICU. In the non-ICU group (n = 317), 4 (2.7%) patients receiving LMWH and 25 (5.1%) receiving UFH were positive for HIT (P = 0.221). In the ICU group (n = 639), 1 (3.1%) patient receiving LMWH and 26 (9.1%) receiving UFH were positive for HIT (P = 0.249). The ICU group, therefore, had a higher cumulative incidence rate of HIT than the non-ICU group (8.5 vs. 4.5%).

CONCLUSION:

HIT was more common in ICU patients than non-ICU patients and in more patients receiving UFH than LMWH, although the differences were not statistically significant. Early diagnosis and appropriate treatment are essential to prevent adverse outcomes in patients with HIT.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Risk_factors_studies / Screening_studies Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Risk_factors_studies / Screening_studies Idioma: En Ano de publicação: 2023 Tipo de documento: Article